Valuation: Noxopharm Limited

Market Cap 26.73M 18.71M 16.26M 15.18M 13.93M 26.27M 1.78B 179M 70.09M 889M 70.26M 68.7M 2.93B P/E 2024
-5.39x
P/E 2025 -3.23x
Enterprise Value 27.65M 19.35M 16.82M 15.7M 14.42M 27.18M 1.84B 185M 72.52M 920M 72.69M 71.08M 3.03B EV / Sales 2024
7.07x
EV / Sales 2025 5.92x
Free-Float
71.75%
Yield 2024 *
-
Yield 2025 -
1 week-21.00%
Current month-3.66%
1 month-15.96%
3 months+11.27%
6 months+21.54%
Current year-15.05%
1 week 0.08
Extreme 0.079
0.1
1 month 0.08
Extreme 0.077
0.1
Current year 0.05
Extreme 0.051
0.11
1 year 0.05
Extreme 0.051
0.14
3 years 0.03
Extreme 0.033
0.16
5 years 0.03
Extreme 0.033
0.63
10 years 0.03
Extreme 0.033
1.8
Manager TitleAgeSince
Chief Executive Officer - 2026-04-14
Director of Finance/CFO - 2019-02-28
Corporate Officer/Principal - 2017-12-31
Director TitleAgeSince
Chairman 70 2016-03-14
Director/Board Member - 2020-03-25
Chairman 71 2020-09-08
Date Insider Type Main position Quantity % Market Cap.
9/20/23 Buy

Chairman

880 0.0003%
9/17/23 Buy

Chairman

253,001 0.0866%
7/3/23 Buy

Chairman

135,281 0.0463%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-21.00%-31.30%+125.71% 16.99M
-0.23%-0.36%-1.31%+13.23% 48.22B
-2.71%-2.99%+398.09%+472.12% 38.79B
-0.71%+9.45%+27.90%+7.89% 38.41B
-0.71%-3.72%+4.94%+52.45% 34.88B
-2.41%+1.96%+11.68%+38.17% 29.19B
-0.66%-2.73%+35.50%+122.17% 16B
-0.19%-3.93% - - 16.05B
+1.36%+0.23%+3.22%+16.56% 13.53B
-3.15%-6.14%-4.82%-36.90% 12.22B
Average -0.94%-0.96%+49.32%+90.16% 24.73B
Weighted average by Cap. -1.10%+0.15%+75.74%+103.46%

Financials

2024 2025
Net sales 2.4M 1.68M 1.46M 1.36M 1.25M 2.36M 160M 16.07M 6.29M 79.84M 6.31M 6.17M 263M 2.82M 1.97M 1.72M 1.6M 1.47M 2.77M 188M 18.89M 7.4M 93.83M 7.41M 7.25M 309M
Net income -3.58M -2.5M -2.18M -2.03M -1.87M -3.52M -239M -23.96M -9.38M -119M -9.41M -9.2M -393M -4.88M -3.42M -2.97M -2.77M -2.55M -4.8M -326M -32.7M -12.81M -162M -12.84M -12.55M -536M
Net Debt -2.32M -1.62M -1.41M -1.32M -1.21M -2.28M -155M -15.53M -6.08M -77.17M -6.1M -5.96M -255M 925K 647K 563K 525K 482K 909K 61.7M 6.19M 2.43M 30.77M 2.43M 2.38M 101M
Logo Noxopharm Limited
Noxopharm Limited is a clinical-stage biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA drug enhancement, and oncology). Chroma is a technology platform, which is focused on development of drug candidates based on a scaffold structure known as functionalized benzopyrans. Sofra technology platform comprises a novel class of drugs targeting inflammatory and autoimmune diseases based on oligonucleotides, the building blocks of DNA, with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-SKN is a novel drug candidate for autoimmune diseases that targets an inflammatory sensor called TLR7.
Employees
-
Date Price Change Volume
26-08-03 A$0.0790 0.00% 128
26-08-03 A$0.0790 -3.66% 82,308
26-07-31 A$0.0820 0.00% 22,449
26-07-30 A$0.0820 -10.87% 191,005
26-07-29 A$0.0920 -8.00% 99,039